On March 16, 2026, Alto Neuroscience closed a $120 million private placement. The announcement made zero mention of ALTO-101 or cognitive impairment associated with schizophrenia. Every dollar was earmarked for ALTO-207, the company's treatment-resistant depression candidate, which was on track to enter a Phase 2b trial in the first half of 2026. Then two weeks later, on April 1, the ALTO-101 Phase 2 readout came in cold. Alto disclosed the financing in an SEC filing. Alto's April 1 press release on Business Wire confirms the program status and timeline.
That is not the sequence of a company caught off guard by a Phase 2 miss. CEO Amit Etkin, who founded Alto in 2019 after a decade as a tenured professor of psychiatry at Stanford, called ALTO-101 an exploratory program in the same press release where he highlighted the company's $275 million cash position. Alto's team page has Etkin's full biography. When the data arrived, Alto did not hesitate: it shelved the cognitive impairment program and said it would explore strategic options, including potential partnering, for the oral formulation. Its stock fell 13.6 percent to $20.16 in pre-market trading that day. Benzinga reported that Alto dipped 13.6% to $20.16 in pre-market trading after the company announced the topline data.
ALTO-101 is a phosphodiesterase-4 (PDE4) inhibitor applied via transdermal patch. The trial enrolled 83 patients across 13 U.S. clinical sites over six weeks, with theta-band inter-trial coherence (theta-ITC), a measure of neural timing consistency recorded on electroencephalography (EEG), as the primary endpoint. In the full cohort, the signal was near-significant at p=0.052 with an effect size of Cohen's d=0.34. In a pre-specified subgroup of 59 patients with more severe cognitive impairment at baseline, the same measure crossed nominal significance at p=0.03 with an effect size of d=0.44. Biospace reported the topline data. The cutoff threshold that defined "more cognitively impaired" is not publicly documented in a way that allows independent verification.
The tolerability story is what makes ALTO-101 potentially worth acquiring. Nausea and vomiting were in line with placebo, which is unusual for a PDE4 inhibitor. The class's signature toxicity is gastrointestinal distress severe enough to limit dosing; apremilast, approved for psoriasis and psoriatic arthritis, is the cautionary tale. The patch delivery appears to have sidestepped the problem by bypassing the gut entirely. Alto's press release has the full tolerability data.
The financing press release and the failure announcement tell a consistent story. Management had already decided which program mattered. When the data came in equivocal, the decision was already made.
The cognitive impairment associated with schizophrenia (CIAS) field has a long history of Phase 2-to-uncertain-future trajectories that makes enrichment strategies rational, if self-defeating in aggregate. PDE4 inhibition is not a speculative hypothesis. Genetic studies have linked PDE4B and PDE4D variants to schizophrenia in large GWAS cohorts, with thousands of associated SNPs catalogued across Finnish and Scottish populations. A 2019 study in Molecular Psychiatry has the full genetic picture. Yet no PDE4 inhibitor has turned a CIAS signal into an approval.
The most recent cautionary example is Boehringer Ingelheim's iclepertin, a glycine transporter-1 (GlyT1) inhibitor. Its Phase 2 trial enrolled 509 patients and showed significant cognitive improvement as measured by the MCCB, but all three Phase 3 CONNEX trials failed in January 2025. The disconnect between Phase 2 promise and Phase 3 failure is so common in CIAS that it has become its own subgenre of drug development literature. The CONNEX trial results are in PubMed.
KarXT, a muscarinic receptor agonist from Karuna Therapeutics that Bristol-Myers Squibb acquired for $14 billion in March 2024, complicates the picture in a useful way. The drug won FDA approval on September 27, 2024 for treating schizophrenia itself, based on its antipsychotic effects in Phase 3. Cognitive improvement was observed in post-hoc analyses of Phase 2 trials, not as a primary endpoint. That distinction matters: KarXT establishes that the muscarinic pathway can produce antipsychotic effects in schizophrenia, and that cognitive signals emerged as a secondary finding. Whether those secondary signals will translate into a CIAS indication remains an open question. KarXT's cognitive data is in PubMed.
The partnering conversation for ALTO-101 therefore has a specific shape. A buyer would not be acquiring a validated asset. They would be acquiring a differentiated tolerability profile, a patch delivery system that appears to solve the PDE4 gastrointestinal problem, and a subgroup hypothesis that might survive a larger trial in a more carefully selected patient population. That requires a buyer who understands enrichment trial design in a field where the standard Phase 2 result has historically not predicted Phase 3 success. The cash position matters for the negotiating table. Alto ended the first quarter with roughly $275 million in cash, pro forma for the March financing. That gives the company approximately two years of runway without needing to partner ALTO-101 at distressed prices. A buyer will have to make a real offer.
Alto's next material catalyst is ALTO-207, a fixed-dose combination of pramipexole, a dopamine D3/D2 agonist, and ondansetron, a 5-hydroxytryptamine-3 (5-HT3) antagonist, designed to treat treatment-resistant depression by mitigating pramipexole's dose-limiting nausea. The combination is grounded in the PAX-D study, a University of Oxford trial published in The Lancet Psychiatry, which showed a Cohen's d of 0.87 for pramipexole versus placebo at 12 weeks, a large effect size by psychiatric trial standards. Alto cited the PAX-D data in its press release. The idea is that ondansetron blocks the 5-HT3 receptor-mediated nausea pathway that constrains how aggressively pramipexole can be titrated, potentially letting patients reach therapeutic doses faster.
The cognitive impairment program is not dead. It is on the block. Whether it finds a buyer willing to run the right trial in the right patient population will determine whether ALTO-101 becomes a footnote or a future approval.
† Add citation to the registered BioSpace source instead, or register the Business Wire source if it was used: 'Alto's April 1 press release on BioSpace confirms the program status and timeline.'
† Add citation to the registered BioSpace source instead, or register the Business Wire source if it was used: 'Alto's April 1 press release on BioSpace confirms the program status and timeline.'
